Scarica l'app Stockscreener
13.13
1.06%
-0.14
Dopo l'orario di chiusura:
13.06
-0.07
-0.53%
Intellia Therapeutics Inc Borsa (NTLA) Ultime notizie
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sahm
Intellia Therapeutics Announces Inducement Grants - National Today
Intellia Grants 67,150 RSUs to 13 New Hires - National Today
Intellia Therapeutics, Inc. (NTLA) Stock Price, News, Quote & History - Yahoo! Finance Canada
13 new Intellia employees get 67,150 stock units over 3 years - Stock Titan
Gene Editing Market Set to Boom Rapidly by 2033 |CRISPR - openPR.com
Intellia Therapeutics Stock Price Forecast. Should You Buy NTLA? - StockInvest.us
Trading Systems Reacting to (NTLA) Volatility - news.stocktradersdaily.com
Why Intellia Therapeutics’ Stock Could Be a Gene‑Editing Goldmine in 2025 – Deep Dive into NTLA’s Prospects - TechStock²
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Trending Industry Today: Intellia Therapeutics Leads Losses In Gene Editing Stocks - Moomoo
Intellia Therapeutics | SCHEDULE 13G/A: Others - Moomoo
Intellia Therapeutics (NTLA) — Vanguard disaggregates holdings, parent reports 0 shares - Stock Titan
Intellia Therapeutics (NASDAQ:NTLA) Rating Increased to Strong-Buy at Truist Financial - MarketBeat
Risk Hedge: Is Intellia Therapeutics Inc a top pick in the sectorQuarterly Market Summary & Reliable Momentum Entry Alerts - baoquankhu1.vn
Bank of America Securities Reaffirms Their Hold Rating on Intellia Therapeutics (NTLA) - The Globe and Mail
Investors in Intellia Therapeutics, Inc. Should Contact Levi & Ko - The National Law Review
Aug Drivers: Does Intellia Therapeutics Inc have a sustainable dividendQuarterly Growth Report & Smart Swing Trading Alerts - baoquankhu1.vn
Hudson Bay Capital Management LP Sells 235,000 Shares of Intellia Therapeutics, Inc. $NTLA - MarketBeat
NTLA SEC FilingsIntellia Therape 10-K, 10-Q, 8-K Forms - Stock Titan
Intellia rises on Q4 earnings & revenue beat, focuses on pipeline - MSN
Intellia jumps as FDA lifts clinical hold on Nex-Z for ATTR-CM - MSN
How Intellia Therapeutics Inc. (NTLA) Affects Rotational Strategy Timing - Stock Traders Daily
Intellia Therapeutics’ stock rocked by patient death in gene therapy trial - MSN
Intellia Therapeutics (NTLA) Soars to New High as Analysts Trigger ‘Buy’ - MSN
NTLA Technical Analysis | Trend, Signals & Chart Patterns | INTELLIA THERAPEUTICS INC (NASDAQ:NTLA) - ChartMill
Best CRISPR Companies for 2026 and How to Invest in Them - The Motley Fool
Intellia Therapeutics, Inc. $NTLA Position Trimmed by Granahan Investment Management LLC - MarketBeat
Farallon Capital Management LLC Purchases Shares of 607,200 Intellia Therapeutics, Inc. $NTLA - MarketBeat
KalVista Pharmaceuticals: Has Potential But With Caveats (NASDAQ:KALV) - Seeking Alpha
Lost Money on Intellia Therapeutics, Inc.(NTLA)? Join Class Acti - GuruFocus
Is Intellia Therapeutics (NTLA) Turning Regulatory Scrutiny Into a Strategic Edge in Gene Editing? - Sahm
Intellia Therapeutics at Leerink Global Healthcare Conference: Gene Editing Prospects - Investing.com Canada
Intellia Therapeutics: Why The Clinical Hold Lift Isn't A Total Victory (NASDAQ:NTLA) - Seeking Alpha
NTLA: Mid-year Phase 3 data could enable a first-in-class, one-time gene editing launch for HAE - TradingView
(NTLA) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Cathie Wood's Intellia Therapeutics Surges 47%: Is It Too Late to Invest? - Intellectia AI
This Cathie Wood Stock Is Up 47% This Year: Is It Too Late to Buy? - Nasdaq
Assessing Intellia Therapeutics (NTLA) Valuation After FDA Hold Lift And New Gene Editing Data - Sahm
Intellia Therapeutics (NASDAQ:NTLA) Upgraded at Wall Street Zen - MarketBeat
Intellia Therapeutics Q4 2025 earnings preview - MSN
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Cathie Wood’s ARK Made Just One Buy Last Session — And It’s A Biotech Stock Up Nearly 30% YTD - Stocktwits
Analysts Offer Insights on Healthcare Companies: Rigel (RIGL), Arcturus Therapeutics (ARCT) and Intellia Therapeutics (NTLA) - The Globe and Mail
Is Intellia Therapeutics (NTLA) Pricing Look Interesting After Strong Year-To-Date Share Gain? - simplywall.st
A Look At Intellia Therapeutics (NTLA) Valuation After Its Recent Share Price Rebound - Yahoo Finance
Amova Asset Management Americas Inc. Cuts Position in Intellia Therapeutics, Inc. $NTLA - MarketBeat
ARK Investment Management LLC Trims Stake in Intellia Therapeutics, Inc. $NTLA - MarketBeat
Jones Trading Upgrades Intellia Therapeutics (NTLA) - Nasdaq
FDA again targets GLP-1 compounders; Intellia to restart heart disease trial - BioPharma Dive
Intellia Therapeutics (NASDAQ:NTLA) Upgraded at JonesTrading - MarketBeat
This Target Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Wednesday - Benzinga
NTLA Stock Upgrade: Jones Trading Raises Intellia Therapeutics t - GuruFocus
HC Wainwright Has Pessimistic Outlook of NTLA Q1 Earnings - MarketBeat
Brookline Capital Maintains Buy on Intellia Therapeutics Inc (NTLA) March 2026 - Meyka
Wells Fargo Raises Price Target for Intellia Therapeutics (NTLA) to $15 | NTLA Stock News - GuruFocus
Intellia (NTLA) CEO John M. Leonard awarded large option and RSU grants - Stock Titan
Intellia (NTLA) EVP receives stock awards and small tax-driven share sale - Stock Titan
Intellia Therapeutics (NTLA) CMO awarded options and RSUs in Form 4 filing - Stock Titan
Intellia Therapeutics (NTLA) CFO granted stock options and RSUs - Stock Titan
Intellia Therapeutics (NTLA) CSO awarded options and RSUs - Stock Titan
Intellia Therapeutics (NTLA) EVP gets stock awards and sells shares for taxes - Stock Titan
Intellia Therapeutics (NTLA) CAO awarded 17,250 restricted stock units - Stock Titan
Intellia Therapeutics (NASDAQ:NTLA) Given New $48.00 Price Target at Canaccord Genuity Group - MarketBeat
FDA’s lifting of clinical holds sends Intellia upwards - The Pharma Letter
Intellia Therapeutics Presents Longer-Term Clinical Data For Lonvoguran Ziclumeran - National Today
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):